Company / Working Capital
GT Biopharma, Inc. Working Capital History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
-$29.4M
FY2020
5-year range
-$61.1M / -$2.1M
FY2016-FY2020
Trend
-1299.6%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital changed -1300% YoY in FY2020, a notable deviation from the 7-year average annual change of -243%.
Based on SEC 10-K filings.
-$29M in FY2020.
Improved from -$61M to -$29M over the past 4 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, working capital decreased 1299.6% year-over-year.
- Peak working capital was recorded in FY2017.
- Lowest working capital in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | -$29.4M | -1299.6% |
| FY2017 | -$2.1M | +96.6% |
| FY2016 | -$61.1M | -111.2% |
| FY2015 | -$28.9M | +0.0% |
| FY2014 | -$28.9M | -362.5% |
| FY2013 | -$6.3M | +1.6% |
| FY2012 | -$6.4M | -24.1% |
| FY2011 | -$5.1M | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026